Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
Public ClinicalTrials.gov record NCT00558467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Flexible Dose Study to Evaluate Efficacy and Safety of Pramipexole Immediate Release (0.125-0.5mg/Day) Versus Placebo for 6 Weeks in Children and Adolescents (Age 6-17 Inclusive) Diagnosed With Tourette Disorder According to DSM IV Criteria.
Study identification
- NCT ID
- NCT00558467
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Interventions
- pramipexole immediate release (IR) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- May 31, 2009
- Completion
- Not listed
- Last update posted
- May 15, 2014
Started 2008
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.644.0026 Boehringer Ingelheim Investigational Site | Bradenton | Florida | — | — |
| 248.644.0025 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 248.644.0006 Boehringer Ingelheim Investigational Site | Columbus | Georgia | — | — |
| 248.644.0012 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 248.644.0005 Boehringer Ingelheim Investigational Site | Cambridge | Massachusetts | — | — |
| 248.644.0003 Boehringer Ingelheim Investigational Site | Manhasset | New York | — | — |
| 248.644.0009 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.644.0018 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.644.0013 Boehringer Ingelheim Investigational Site | Orangeburg | New York | — | — |
| 248.644.0029 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 248.644.0010 Boehringer Ingelheim Investigational Site | Providence | Rhode Island | — | — |
| 248.644.0030 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 248.644.0008 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 248.644.0023 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00558467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00558467 live on ClinicalTrials.gov.